1-2 of 2
Jérome Jaubert
Close
Sort by
Journal Articles

High Efficacy and Particular Safety Profile of Imatinib Mesylate (Glivec®) in Elderly Patients with CML in Chronic Phase: Results of the AFR04 Prospective Study.

Philippe Rousselot, Franck Nicolini, François Xavier Mahon, Delphine Réa, Jérome Jaubert, Christian Berthou, Josy Reiffers, Joelle Guilhot, François Guilhot
Journal: Blood
Blood (2007) 110 (11): 1039.
https://doi.org/10.1182/blood.V110.11.1039.1039
Published: 2007
Journal Articles

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

Clinical Trials & Observations
Thierry Facon, Jean-Yves Mary, Brigitte Pégourie, Michel Attal, Marc Renaud, Alain Sadoun, Laurent Voillat, Véronique Dorvaux, Cyrille Hulin, Gérard Lepeu, Jean-Luc Harousseau, Jean-Paul Eschard, Augustin Ferrant, Michel Blanc, Frédéric Maloisel, Hubert Orfeuvre, Jean-François Rossi, Isabelle Azaïs, Mathieu Monconduit, Philippe Collet, Bruno Anglaret, Ibrahim Yakoub-Agha, Marc Wetterwald, Houchingue Eghbali, Marie-Christine Vekemans, Hervé Maisonneuve, Jacques Troncy, Bernard Grosbois, Chantal Doyen, Antoine Thyss, Jérome Jaubert, Philippe Casassus, Béatrice Thielemans, Régis Bataille, for the Intergroupe Francophone du Myélome (IFM) group
Journal: Blood
Blood (2006) 107 (4): 1292–1298.
https://doi.org/10.1182/blood-2005-04-1588
Published: 2006